Skip to content
Biodatica
Start free

Pharmasaga Co. Ltd.

Taipei

OncologymRNAPhase I
Compare Sign in to watch

What changed

Phase I trial registered: Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

88no change

Momentum 88 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

932 pre-ticker oncology companies at Phase I

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    NA registered

    Apr 27, 2026

    Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Endometrial Cancer, Von Hippel Lindau Disease · RECRUITING · sponsor: Peking University First Hospital · 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

    ClinicalTrials.gov · NCT07557225 (opens the source filing in a new tab)

  2. Grant

    K99 · $128k · non-dilutive

    Jul 1, 2025

    COLUMBIA UNIV NEW YORK MORNINGSIDE · PI LIU, MENGRUI · NCI · award ends Jun 30, 2027 · Inhalable Extracellular Vesicles Engineering for Lung Cancer Treatment

    NIH RePORTER · NIH RePORTER 11214348 (opens the source filing in a new tab)

  3. Trial

    NA registered

    Aug 1, 2024

    Colo-rectal Cancer, Colon Lesion · RECRUITING · sponsor: National Taiwan University Hospital · Compare the Patient Satisfaction and Effectiveness After Novel Application-based or Conventional Health Education of Bowel Preparation for Colonoscopy

    ClinicalTrials.gov · NCT06560671 (opens the source filing in a new tab)

  4. Grant

    R01 · $261k · non-dilutive

    Apr 15, 2024

    UNIVERSITY OF FLORIDA · PI LIU, MEI · NIDDK · award ends Mar 31, 2027 · Personalized Machine Learning for Acute Kidney Injury Prediction and Prognosis

    NIH RePORTER · NIH RePORTER 11073027 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Dec 22, 2023

    Type II Diabetes · COMPLETED · sponsor: Pharmasaga Co. Ltd. · Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

    ClinicalTrials.gov · NCT05176210 (opens the source filing in a new tab)

  6. Grant

    U01 · $500k · non-dilutive

    Jul 1, 2023

    NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LIU, MENGLING · NIOSH · award ends Jun 30, 2026 · Complex WTC Exposures Impacting Persistent Large and Small Airflow Limitation and Vulnerable Subgroups in the WTC Survivor Population

    NIH RePORTER · NIH RePORTER 11074513 (opens the source filing in a new tab)

  7. Grant

    R01 · $461k · non-dilutive

    May 1, 2022

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, MINGXIA · NIA · award ends Apr 30, 2027 · Multi-Site Neuroimage Harmonization for Personalized Brain Disorder Analysis

    NIH RePORTER · NIH RePORTER 11212120 (opens the source filing in a new tab)

  8. Grant

    SC1 · $355k · non-dilutive

    Apr 11, 2022

    MOREHOUSE SCHOOL OF MEDICINE · PI LIU, MINGLI · NIGMS · award ends Mar 31, 2027 · TRPM7 induces tumorigenesis and stemness through Notch activation in glioma

    NIH RePORTER · NIH RePORTER 11044187 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources